Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones Post published:June 2, 2023 Post category:Press Release
Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application. Post published:May 26, 2023 Post category:Press Release
Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA Post published:May 19, 2023 Post category:Press Release
Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB Post published:May 11, 2023 Post category:Press Release
Terran Biosciences announces publication of PCT patent application covering novel non-hallucinogenic psychoplastogens, including derivatives of DMT and ibogaine with improved pharmacokinetics and engagement at target receptors Post published:May 9, 2023 Post category:Press Release